Daniel Tetetla-Castro, Guiomar de Jesús Cruz-Martín, Angélica Castro-Ríos
{"title":"[Changes in hypertensive control 2020-2021 in a family medicine unit].","authors":"Daniel Tetetla-Castro, Guiomar de Jesús Cruz-Martín, Angélica Castro-Ríos","doi":"10.5281/zenodo.11397116","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High blood pressure causes 9.4 million deaths worldwide annually (12.8% of total mortality). With the start of the COVID-19 pandemic and containment measures, the patterns of care for these patients changed.</p><p><strong>Objective: </strong>To evaluate the changes in hypertensive control of patients treated at UMF 18 of Tabasco before and after the appearance of COVID-19.</p><p><strong>Material and methods: </strong>Retrospective longitudinal observational study that included a random sample of 326 patients. Hypertensive control was evaluated in accordance with the current Clinical Practice Guideline. Information was collected on blood pressure, dyslipidemia, and glycated hemoglobin for diabetics, as well as other clinical variables and sociodemographic information. The proportion of patients who remained in hypertensive control, worsened or never remained in control was compared between the two periods. Associated factors were identified through multinomial regression analysis.</p><p><strong>Results: </strong>Before the pandemic, in 2020, 79.1% of patients had blood pressure levels under control, by 2021 it dropped to 50%. T2 diabetes comorbidity was the most important risk factor for lack of control, which after the appearance of COVID-19 almost doubled its effect.</p><p><strong>Conclusions: </strong>A decrease of 29.1% was recorded in compliance with hypertensive control. Groups with greater difficulty in achieving therapeutic goals were identified, highlighting the economically active population.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.11397116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: High blood pressure causes 9.4 million deaths worldwide annually (12.8% of total mortality). With the start of the COVID-19 pandemic and containment measures, the patterns of care for these patients changed.
Objective: To evaluate the changes in hypertensive control of patients treated at UMF 18 of Tabasco before and after the appearance of COVID-19.
Material and methods: Retrospective longitudinal observational study that included a random sample of 326 patients. Hypertensive control was evaluated in accordance with the current Clinical Practice Guideline. Information was collected on blood pressure, dyslipidemia, and glycated hemoglobin for diabetics, as well as other clinical variables and sociodemographic information. The proportion of patients who remained in hypertensive control, worsened or never remained in control was compared between the two periods. Associated factors were identified through multinomial regression analysis.
Results: Before the pandemic, in 2020, 79.1% of patients had blood pressure levels under control, by 2021 it dropped to 50%. T2 diabetes comorbidity was the most important risk factor for lack of control, which after the appearance of COVID-19 almost doubled its effect.
Conclusions: A decrease of 29.1% was recorded in compliance with hypertensive control. Groups with greater difficulty in achieving therapeutic goals were identified, highlighting the economically active population.